anti-CCR8 monoclonal antibody RO7502175

A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody directed against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody RO7502175 targets and binds to the N-terminus of CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T regulatory (TITR) cells in the tumor microenvironment (TME). This depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reverse the suppression of CD8+ effector T cells and reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.